entertainment -WSS

entertainment

author：knowledge 2025-10-02 10:38:40 - browse：5774

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

The drug, which will be sold under the brand name Zurzuvae, is not meant to be taken chronically. Patients take it orally for 14 days. In two clinical trials, the drug was found to significantly improve depressive symptoms more than a placebo. The effect was maintained for four weeks after treatment.

“Maternal mental health has been sidelined for far too long, but today’s approval of Zurzuvae helps to change that. Women have been waiting for an oral medicine that can specifically and rapidly improve the symptoms of PPD and we are proud to be able to deliver that,” said Barry Greene, Sage’s CEO, in a press release.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Custom gene therapy hints at new path for rare disease treatments

WSS

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Woman gored by Bison at Yellowstone

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

J&J expands global access to TB drug amid advocacy campaign

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

focus

entertainment

knowledge

Medical leaders decry Supreme Court decision on affirmative action

How dance can help nurses traumatized by Covid

Moonlake's readout produced a cash windfall. Risks remain

Congress likely to miss an opportunity to fix drug shortages issue

Medical leaders decry Supreme Court decision on affirmative action

Grail faces three suits alleging harassment, retaliation

Cancer drug shortages should be causing more outrage

Startup Neumora takes a novel depression drug to Phase 3

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

explore

FDA approves RSV monoclonal antibody for infants, toddlers

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Europe sees delivery challenges ahead on Alzheimer's therapies

How Medicaid coverage policies for immigrants impact new moms

Sanofi seeks simpler, safer CRISPR sickle cell cure

Can CDC director Mandy Cohen drive consensus in Washington?

focus

focus

focus

entertainment